Literature DB >> 21960058

Type 2B-like acquired von Willebrand syndrome.

Toshio Shigekiyo1, Etsuko Sekimoto2, Atsuhisa Shirakami2, Hiroshi Yamaguchi2, Hironobu Shibata2, Shuji Ozaki2, Kazuya Kanda3, Seiya Saito4, Nobuo Satake5, Osamu Fujino6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21960058     DOI： 10.1007/s12185-011-0938-0

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  10 in total

Review 1.  Acquired von Willebrand syndrome: from pathophysiology to management.

Authors:  A Veyradier; C S Jenkins; E Fressinaud; D Meyer
Journal:  Thromb Haemost       Date:  2000-08       Impact factor: 5.249

Review 2.  Acquired von Willebrand syndrome: is it an extremely rare disorder or do we see only the tip of the iceberg?

Authors:  A B Federici
Journal:  J Thromb Haemost       Date:  2008-01-25       Impact factor: 5.824

3.  Structure of the human blood platelet membrane glycoprotein Ib alpha gene.

Authors:  R H Wenger; N Kieffer; A N Wicki; K J Clemetson
Journal:  Biochem Biophys Res Commun       Date:  1988-10-14       Impact factor: 3.575

4.  Platelet aggregation induced by a monoclonal antibody to the A1 domain of von Willebrand factor.

Authors:  H Depraetere; N Ajzenberg; J P Girma; C Lacombe; D Meyer; H Deckmyn; D Baruch
Journal:  Blood       Date:  1998-05-15       Impact factor: 22.113

5.  Diagnosis and therapeutic management in a patient with type 2B-like acquired von Willebrand syndrome.

Authors:  Ralf Karger; Monika Weippert-Kretschmer; Ulrich Budde; Volker Kretschmer
Journal:  Blood Coagul Fibrinolysis       Date:  2011-03       Impact factor: 1.276

6.  Acquired von Willebrand syndrome: data from an international registry.

Authors:  A B Federici; J H Rand; P Bucciarelli; U Budde; P J van Genderen; H Mohri; D Meyer; F Rodeghiero; J E Sadler
Journal:  Thromb Haemost       Date:  2000-08       Impact factor: 5.249

7.  Absence of a bleeding tendency in severe acquired von Willebrand's disease. The role of platelet von Willebrand factor in maintaining normal hemostasis.

Authors:  J Drouin; D P Lillicrap; C A Izaguirre; M Sutherland; S Windsor; K Benford; H Hoogendorn; A R Giles
Journal:  Am J Clin Pathol       Date:  1989-10       Impact factor: 2.493

8.  A monoclonal antibody directed against human von Willebrand factor induces type 2B-like alterations.

Authors:  H Ulrichts; J Harsfalvi; L Bene; J Matko; J Vermylen; N Ajzenberg; D Baruch; H Deckmyn; I Tornai
Journal:  J Thromb Haemost       Date:  2004-09       Impact factor: 5.824

9.  A new ELISA assay for diagnosis of acquired von Willebrand syndrome.

Authors:  C Siaka; L Rugeri; C Caron; J Goudemand
Journal:  Haemophilia       Date:  2003-05       Impact factor: 4.287

10.  Human von Willebrand factor gene and pseudogene: structural analysis and differentiation by polymerase chain reaction.

Authors:  D J Mancuso; E A Tuley; L A Westfield; T L Lester-Mancuso; M M Le Beau; J M Sorace; J E Sadler
Journal:  Biochemistry       Date:  1991-01-08       Impact factor: 3.162
  10 in total
  1 in total

1.  Utility of Bruton's Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström's Macroglobulinemia).

Authors:  Maroun Bou Zerdan; Jason Valent; Maria Julia Diacovo; Karl Theil; Chakra P Chaulagain
Journal:  Adv Hematol       Date:  2022-01-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.